Pharmacologic approaches to the treatment of obesity
$1,239,818ZIAFY2019DKNIH
National Institute Of Diabetes And Digestive And Kidney Diseases
Investigators
Linked publications & trials
Paper 39067024Paper 38657735Paper 36858190Paper 36781825Paper 33657388Paper 32691633Paper 32295065Paper 32294435Paper 32271569Paper 32229422Paper 31150063Paper 31067015Paper 31028699Paper 30822301Paper 30605331Paper 30349101Paper 29812984Paper 29697140Paper 29107299Paper 28683281Paper 27468065Paper 27385608Paper 26562312Paper 26053335Paper 26042200Paper 25675384Paper 25160589Paper 24981835Paper 24872412Paper 24465761Paper 23643386Paper 22768831Paper 22205519Paper 22162541Paper 21878513Paper 21832118Paper 21602305Paper 21493064Paper 21442160Paper 21354793Paper 21191377Paper 21036912
Abstract
Obesity is a huge and increasing medical problem, with inadequate therapeutic options. One approach to the treatment of obesity is long-term pharmacotherapy. Drugs approved in the United States include orlistat, lorcaserin, phentermine/topiramate, buproprion/naltrexone, and liraglutide (high dose). The limited efficacy of single agents has led to the idea that additional agents and combination therapy are required. Progress in FY2019 includes the following: We are continuing our work on understanding thermal biology of mice and the similarities and differences to humans. We are also continuing to understand the various types of hypothermia that a mouse can achieve.
View original record on NIH RePORTER →